natgillin/translations-raw huggingface dataset:
Stomatitis Oesophagitis Vomiting Diarrhoea Dyspepsia Abdominal pain Enteritis Colitis 
Bolezni prebavil navzea stomatitis ezofagitis bruhanje driska dispepsija abdominalne bolečine enteritis kolitis zaprtost predrtje črevesja ileus razjeda prebavil
Using a syringe fitted with a needle, aseptically withdraw 10 ml of sterile water for injections. 
S pomočjo injekcijske brizge z iglo aseptično odvzemite 10 ml sterilne vode za injekcije.
Using a syringe fitted with a needle, aseptically withdraw 1.5 ml of sterile water for injection. 
S pomočjo injekcijske brizge z iglo aseptično odvzemite 1,5 ml sterilne vode za injekcije.
Each TEPADINA vial must be reconstituted with 10 ml of sterile water for injection. 
Vsako vialo TEPADINA je treba rekonstituirati z 10 ml sterilne vode za injiciranje.
Blood bilirubin increased Transaminases increased Blood creatinine increased Aspartate aminotransferase increased Alanine aminotransferase increased 
Preiskave zvečane vrednosti bilirubina v krvi zvečana vrednost transaminaz zvečana vrednost kreatinina v krvi zvečana vrednost aspartataminotransferaze zvečana vrednost alaninaminotransferaze zvečane vrednosti sečnine v krvi nenormalne vrednosti elektrolitov v krvi zvečano razmerje protrombinskega časa
After reconstitution with 10 ml of water for injections, each ml of solution contains 10 mg thiotepa (10 mg/ml). 
Po rekonstituciji z 10 ml vode za injekcije en ml raztopine vsebuje 10 mg tiotepe (10 mg/ml).
One vial of powder contains 100 mg thiotepa. 
Ena viala s praškom vsebuje 100 mg tiotepe.
After reconstitution with 1.5 ml of water for injections, each ml of solution contains 10 mg thiotepa (10 mg/ml). 
Po rekonstituciji z 1,5 ml vode za injekcije en ml raztopine vsebuje 10 mg tiotepe (10 mg/ml).
One vial of powder contains 15 mg thiotepa. 
Ena viala s praškom vsebuje 15 mg tiotepe.
Erythema Desquamation Pigmentation disorder 
Bolezni kože in podkožja izpuščaj eritem deskvamacija motnja pigmentacije
Pigmentation disorder Erythrodermic psoriasis 
Bolezni kože in podkožja izpuščaj srbečica alopecija eritem motnja pigmentacije eritrodermična psoriaza
TRM values ranged from 0% to 21% at 1 year, confirming the safety of the conditioning treatment including thiotepa for autologous HPCT in adult patients with haematological diseases. 
Vrednosti TRM so od 0 do 21 % za eno leto, kar potrjuje varnost pripravljalnega zdravljenja s tiotepo za avtologno PKMC pri odraslih bolnikih s hematološkimi boleznimi.
- anxiety, confusion - abnormal bulging outward of one of the arteries in the brain (intracranial aneurysm) - creatinine elevated - allergic reactions - occlusion of a blood vessel (embolism) - heart rhythm disorder - heart inability - cardiovascular inability - oxygen deficiency - fluid accumulation in the lungs (pulmonary oedema) - pulmonary bleeding - respiratory arrest - blood in the urine (haematuria) and moderate renal insufficiency - inflammation of the urinary bladder - discomfort in urination and decrease in urine output (disuria and oliguria) - increase in the amount of nitrogen components in the blood stream (BUN increase) - cataract - inability of the liver - cerebral haemorrhage - cough - constipation and upset stomach - obstruction of the bowel - perforation of stomach - changes in muscle tone - gross lack of coordination of muscle movements - bruises due to a low platelet count - menopausal symptoms - cancer (second primary malignancies) - abnormal brain function - male and female infertility 
- kri v urinu (hematurija) in zmerna ledvična insuficienca - vnetje sečnega mehurja - bolečine pri uriniranju in manjša količina izločenega urina (dizurija in oligurija) - večja količina dušikovih sestavin v krvi (zvišanje dušika sečnine v krvi - BUN)
If thiotepa accidentally contacts mucous membranes, they must be flushed thoroughly with water. 
Če pride tiotepa nenamerno v stik s sluznico, sluznico temeljito sperite z vodo.
Each TEPADINA vial must be reconstituted with 1.5 ml of sterile water for injection. 
Vsako vialo TEPADINA je treba rekonstituirati z 1,5 ml sterilne vode za injiciranje.
Leukopenia Thrombocytopenia Febrile neutropenia Anaemia 
Bolezni krvi in limfatičnega sistema levkopenija trombocitopenija febrilna nevtropenija anemija pancitopenija granulocitopenija
TEPADINA is supplied as 100 mg powder for concentrate for solution for infusion. 
Zdravilo TEPADINA je na voljo kot 100 mg prašek za koncentrat za raztopino za infundiranje.
Chemical and physical in-use stability after dilution has been demonstrated for 24 hours when stored at 2°C -8°C and for 4 hours when stored at 25°C. 
Dokazano je bilo, da je po redčenju raztopina kemijsko in fizikalno stabilna 24 ur, če je bila hranjena pri 2 °C -8 °C in 4 ure, če je bila hranjena pri 25 °C.
Chemical and physical in-use stability after dilution has been demonstrated for 24 hours when stored at 2°C-8°C and for 4 hours when stored at 25°C. 
Dokazano je bilo, da je po redčenju raztopina kemijsko in fizikalno stabilna 24 ur, če je bila hranjena pri 2 °C-8 °C, in 4 ure, če je bila hranjena pri 25 °C.
Live virus and bacterial vaccines must not be administered to a patient receiving an immunosuppressive chemotherapeutic agent and at least three months must elapse between discontinuation of therapy and vaccination. 
Posebne interakcije s tiotepo Živa virusna in bakterijska cepiva se ne smejo uporabljati pri bolnikih, ki prejemajo zdravilo za zaviranje imunske odzivnosti.
TEPADINA is supplied as 15 mg powder for concentrate for solution for infusion. 
Zdravilo TEPADINA je na voljo kot 15 mg prašek za koncentrat za raztopino za infundiranje.
The recommended dose in haematological diseases ranges from 185 mg/m2/day (5 mg/kg/day) to 481 mg/m2/day (13 mg/kg/day) divided in one or two daily infusions, administered from 1 up to 3 consecutive days before allogeneic HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 555 mg/m2 (15 mg/kg), during the time of the entire conditioning treatment. 
Priporočeni odmerek pri hematoloških boleznih je od 185 mg/m2 na dan (5 mg/kg/dan) do 481 mg/m2 na dan (13 mg/kg/dan), razdeljen na eno ali dve infuziji na dan, in se daje 1 do 3 zaporedne dni pred alogensko PKMC, odvisno od kombinacije z drugimi kemoterapevtiki, ne da bi se presegel skupni največji kumulativni odmerek 555 mg/m2 (15 mg/kg) v času celotnega pripravljalnega zdravljenja.
The recommended dose is 250 mg/m2/day (6.76 mg/kg/day) as a single daily infusion, administered in 2 consecutive days before autologous HPCT, without exceeding the total maximum cumulative dose of 500 mg/m2 (13.51 mg/kg), during the time of the entire conditioning treatment. 
Priporočeni odmerek je 250 mg/m2/dan (6,76 mg/kg/dan) v obliki ene infuzije na dan, ki se daje dva zaporedna dneva pred avtologno PKMC, ne da bi se presegel skupni največji kumulativni odmerek 500 mg/m2 (13,51 mg/kg) v času celotnega pripravljalnega zdravljenja.
After reconstitution with 1.5 ml of water for injection, each ml contains 10 mg thiotepa. 
Po rekonstituciji z 1,5 ml vode za injekcije en ml raztopine vsebuje 10 mg tiotepe.
Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): RRM values ranging from 0% to 26.7% have been reported. 
Z režimom povezana umrljivost in s presaditvijo povezana umrljivost: poročali so o vrednostih RRM med 0 in 26,7 %.
Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): RRM values ranging from 2.5% to 29% have been reported. 
Z režimom povezana umrljivost (RRM: Regimen Related Mortality) in s presaditvijo povezana umrljivost (TRM: Transplant related Mortality): poročali so o vrednostih RRM od 2,5 do 29 odstotkov.
In some of the conditioning treatments evaluated, relapse rates lower than 60% have also been reported at 5 years. 
Pri nekaterih ocenjenih pripravljalnih zdravljenjih so poročali tudi o stopnjah ponovitve,
TEPADINA 15 mg powder for concentrate for solution for infusion 
TEPADINA 15 mg prašek za koncentrat za raztopino za infundiranje
TRM values ranged from 0% to 7.4% confirming the safety of the conditioning treatment including thiotepa for autologous HPCT in adult patients with solid tumours. 
Vrednosti TRM so od 0 do 7,4 odstotkov, kar potrjuje varnost pripravljalnega zdravljenja s tiotepo za avtologno PKMC pri odraslih bolnikih s čvrstimi tumorji.
This leaflet was last revised in: 
Pogostnost je opredeljena kot sledi:
The recommended dose ranges from 200 mg/m2/day (8 mg/kg/day) to 250 mg/m2/day (10 mg/kg/day) divided in two daily infusions, administered before allogeneic HPCT without exceeding the total maximum cumulative dose of 250 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment. 
Priporočeni odmerek je od 200 mg/m2 na dan (8 mg/kg/dan) do 250 mg/m2 na dan (10 mg/kg/dan), razdeljen na dve infuziji na dan pred alogensko PKMC, ne da bi se presegel skupni največji kumulativni odmerek 250 mg/m2 (10 mg/kg) v času celotnega pripravljalnega zdravljenja.
TRM values ranged from 0% to 30% confirming the safety of the conditioning treatment including thiotepa for allogeneic HPCT in paediatric patients with haematological diseases. 
Vrednosti TRM so bile med 0 in 30 %, kar potrjuje varnost pripravljalnega zdravljenja s tiotepo za alogensko PKMC pri pediatričnih bolnikih s hematološkimi boleznimi.
TEPADINA can impair male and female fertility. 
Zdravilo TEPADINA lahko zmanjša plodnost moških in žensk.
TEPADINA 100 mg powder for concentrate for solution for infusion 
TEPADINA 100 mg prašek za koncentrat za raztopino za infundiranje
Frequencies are defined as: very common (≥1/10), common ((≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) very rare (<1/10,000), not known (cannot be estimated from the available data). 
< 1/1.000), zelo redki (< 1/10.000); neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
TRM values ranged from 0% to 18% confirming the safety of the conditioning treatments including thiotepa for autologous HPCT in paediatric patients with solid tumours. 
Vrednosti TRM so bile med 0 in 18 %, kar potrjuje varnost pripravljalnega zdravljenja s tiotepo za avtologno PKMC pri pediatričnih bolnikih s čvrstimi tumorji.
Hearing impaired Ototoxicity Tinnitus 
vključno z motnjami labirinta motnje sluha ototoksičnost tinitus
Idiopathic pneumonia syndrome Pulmunary haemorrage Pulmonary oedema 
Bolezni dihal, prsnega koša in mediastinalnega prostora pljučnica sindrom idiopatske pnevmonije pljučna krvavitev pljučni edem epistaksa hipoksija zastoj dihanja
The recommended dose is 125 mg/m2/day (5 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before allogeneic HPCT, without exceeding the total maximum cumulative dose of 375 mg/m2 (15 mg/kg), during the time of the entire conditioning treatment. 
REFRAKTARNA CITOPENIJA Priporočeni odmerek je 125 mg/m2/dan (5 mg/kg/dan) v obliki ene infuzije na dan, ki se daje tri zaporedne dni pred alogensko PKMC, ne da bi se presegel skupni največji kumulativni odmerek 375 mg/m2 (15 mg/kg) v času celotnega pripravljalnega zdravljenja.
Allogeneic HPCT 
ALOGENSKA PKMC
ALLOGENEIC HPCT 
Alogenska PKMC
Dysuria Oliguria Renal failure Cystitis Haematuria 
Bolezni sečil hemoragični cistitis dizurija oligurija odpoved ledvic cistitis hematurija
CENTRAL NERVOUS SYSTEM (CNS) LYMPHOMA The recommended dose is 185 mg/m2/day (5 mg/kg/day) as a single daily infusion, administered for 2 consecutive days before autologous HPCT, without exceeding the total maximum cumulative dose of 370 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment. 
LIMFOM V OSREDNJEM ŽIVČEVJU Priporočeni odmerek je 185 mg/m2 na dan (5 mg/kg/dan) v obliki ene infuzije na dan in se daje dva zaporedna dneva pred avtologno PKMC, ne da bi se presegel skupni največji kumulativni odmerek 370 mg/m2 (10 mg/kg) v času celotnega pripravljalnega zdravljenja
After reconstitution with 10 ml of water for injection, each ml contains 10 mg thiotepa. 
Po rekonstituciji z 10 ml vode za injekcije en ml raztopine vsebuje 10 mg tiotepe.
TEPADINA posology is reported, in adult and paediatric patients, according to the type of HPCT (autologous or allogeneic) and disease. 
PKMC (avtologna ali alogenska) in bolezen.
The recommended dose ranges from 125 mg/m2/day (3.38 mg/kg/day) to 300 mg/m2/day (8.10 mg/kg/day) as a single daily infusion, administered from 2 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 900 mg/m2 (24.32 mg/kg), during the time of the entire conditioning treatment. 
Priporočeni odmerek je od 125 mg/m2 na dan (3,38 mg/kg/dan) do 300 mg/m2 na dan (8,10 mg/kg/dan) v obliki ene infuzije na dan, ki se daje 2 do 4 zaporedne dni pred avtologno PKMC, odvisno od kombinacije z drugimi kemoterapevtiki, ne da bi se presegel skupni največji kumulativni odmerek 900 mg/m2 (24,32 mg/kg) v času celotnega pripravljalnega zdravljenja.
The recommended dose ranges from 150 mg/m2/day (4.05 mg/kg/day) to 250 mg/m2/day (6.76 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 750 mg/m2 (20.27 mg/kg), during the time of the entire conditioning treatment. 
Priporočeni odmerek je od 150 mg/m2 na dan (4,05 mg/kg/dan) do 250 mg/m2 na dan (6,76 mg/kg/dan) v obliki ene infuzije na dan in se daje 3 zaporedne dni pred avtologno PKMC, odvisno od kombinacije z drugimi kemoterapevtiki, ne da bi se presegel skupni največji kumulativni odmerek 750 mg/m2 (20,27 mg/kg) v času celotnega pripravljalnega zdravljenja.
GERM CELL TUMOURS 
GERMINALNI TUMORJI
The recommended dose in solid tumours ranges from 150 mg/m2/day (6 mg/kg/day) to 350 mg/m2/day (14 mg/kg/day) as a single daily infusion, administered from 2 up to 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 1050 mg/m2 (42 mg/kg), during the time of the entire conditioning treatment. 
Priporočeni odmerek pri čvrstih tumorjih je od 150 mg/m2 na dan (6 mg/kg/dan) do 350 mg/m2 na dan (14 mg/kg/dan) v obliki ene infuzije na dan in se daje 2 do 3 zaporedne dni pred avtologno PKMC, odvisno od kombinacije z drugimi kemoterapevtiki, ne da bi se presegel skupni največji kumulativni odmerek 1050 mg/m2 (42 mg/kg) v času celotnega pripravljalnega zdravljenja.
Respiratory, thoracic and mediastinal disorders 
- zvišana raven jetrnih, ledvičnih in prebavnih encimov
(8.10 mg/kg/day) as a single daily infusion, administered from 2 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 900 mg/m2 (24.32 mg/kg), during the time of the entire conditioning treatment. 
300 mg/m2 na dan (8,10 mg/kg/dan) v obliki ene infuzije na dan, ki se daje 2 do 4 zaporedne dni pred avtologno PKMC, odvisno od kombinacije z drugimi kemoterapevtiki, ne da bi se presegel skupni največji kumulativni odmerek 900 mg/m2 (24,32 mg/kg) v času celotnega pripravljalnega zdravljenja.
The recommended dose ranges from 125 mg/m2/day (3.38 mg/kg/day) to 250 mg/m2/day (6.76 mg/kg/day) divided in one or two daily infusions, administered from 3 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 750 mg/m2 (20.27 mg/kg), during the time of the entire conditioning treatment. 
Priporočeni odmerek je od 125 mg/m2 na dan (3,38 mg/kg/dan) do 250 mg/m2 na dan (6,76 mg/kg/dan), razdeljen na eno ali dve infuziji na dan, in se daje 3 do 4 zaporedne dni pred avtologno PKMC, odvisno od kombinacije z drugimi kemoterapevtiki, ne da bi se presegel skupni največji kumulativni odmerek 750 mg/m2 (20,27 mg/kg) v času celotnega pripravljalnega zdravljenja.
The recommended dose ranges from 250 mg/m2/day (10 mg/kg/day) to 350 mg/m2/day (14 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 1050 mg/m2 (42 mg/kg), during the time of the entire conditioning treatment. 
Priporočeni odmerek je od 250 mg/m2 na dan (10 mg/kg/dan) do 350 mg/m2 na dan (14 mg/kg/dan) v obliki ene infuzije na dan in se daje 3 zaporedne dni pred avtologno PKMC, odvisno od kombinacije z drugimi kemoterapevtiki, ne da bi se presegel skupni največji kumulativni odmerek 1050 mg/m2 (42 mg/kg) v času celotnega pripravljalnega zdravljenja.
Idiopathic pneumonia syndrome Epistaxis 
Očesne bolezni konjuktivitis katarakta
TEPADINA 100 mg powder for concentrate for solution for infusion Thiotepa 
TEPADINA 100 mg prašek za koncentrat za raztopino za infundiranje tiotepa
TEPADINA must be reconstituted with 10 ml of sterile water for injection. 
Rekonstitucija Zdravilo TEPADINA se rekonstituira z 10 ml sterilne vode za injekcije.
The recommended dose in solid tumours ranges from 120 mg/m2/day (3.24 mg/kg/day) to 250 mg/m2/day (6.76 mg/kg/day) divided in one or two daily infusions, administered from 2 up to 5 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 800 mg/m2 (21.62 mg/kg), during the time of the entire conditioning treatment. 
Priporočeni odmerek pri čvrstih tumorjih je od 120 mg/m2 na dan (3,24 mg/kg/dan) do 250 mg/m2 na dan (6,76 mg/kg/dan), razdeljen na eno ali dve infuziji na dan, in se daje 2 do 5 zaporednih dni pred avtologno PKMC, odvisno od kombinacije z drugimi kemoterapevtiki, ne da bi se presegel skupni največji kumulativni odmerek 800 mg/m2 (21,62 mg/kg) v času celotnega pripravljalnega zdravljenja.
TEPADINA must be reconstituted with 1.5 ml of sterile water for injection. 
Rekonstitucija Zdravilo TEPADINA se rekonstituira z 1,5 ml sterilne vode za injekcije.
TEPADINA 15 mg powder for concentrate for solution for infusion Thiotepa 
TEPADINA 15 mg prašek za koncentrat za raztopino za infundiranje tiotepa
BREAST CANCER 
RAK DOJK
Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): RRM values ranging from 0% to 2% have been reported. 
Z režimom povezana umrljivost in s presaditvijo povezana umrljivost: Poročali so o vrednostih RRM od 0 do 2 odstotkov.
The recommended dose is 370 mg/m2/day (10 mg/kg/day) divided in two daily infusions, administered before allogeneic HPCT, without exceeding the total maximum cumulative dose of 370 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment. 
TALASEMIJA Priporočeni odmerek je 370 mg/m2/dan (10 mg/kg/dan), razdeljen na dve infuziji na dan pred alogensko PKMC, ne da bi se presegel skupni največji kumulativni odmerek 370 mg/m2 (10 mg/kg) v času celotnega pripravljalnega zdravljenja.
PREPARATION GUIDE TEPADINA 100 mg powder for concentrate for solution for infusion 
NAVODILO ZA PRIPRAVO TEPADINA 100 mg prašek za koncentrat za raztopino za infundiranje
The recommended dose is 250 mg/m2/day (10 mg/kg/day) divided in two daily infusions, administered before allogeneic HPCT, without exceeding the total maximum cumulative dose of 250 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment. 
LEVKEMIJA Priporočeni odmerek je 250 mg/m2/dan (10 mg/kg/dan), razdeljen na dve infuziji na dan pred alogensko PKMC, ne da bi se presegel skupni največji kumulativni odmerek 250 mg/m2 (10 mg/kg) v času celotnega pripravljalnega zdravljenja.
The recommended dose in lymphoma is 370 mg/m2/day (10 mg/kg/day) divided in two daily infusions before allogeneic HPCT, without exceeding the total maximum cumulative dose of 370 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment. 
LIMFOM Priporočeni odmerek pri limfomu je 370 mg/m2/dan (10 mg/kg/dan), razdeljen na dve infuziji na dan pred alogensko PKMC, ne da bi se presegel skupni največji kumulativni odmerek 370 mg/m2 (10 mg/kg) v času celotnega pripravljalnega zdravljenja.
Haemorrhage Embolism 
REFRAKTARNA CITOPENIJA
Pancytopenia Granulocytopenia 
Shranjevanje zdravila TEPADINA
Thrombocytopenia Febrile neutropenia Anaemia 
Bolezni krvi in limfatičnega sistema trombocitopenija febrilna nevtropenija anemija pancitopenija granulocitopenija
PREPARATION GUIDE TEPADINA 15 mg powder for concentrate for solution for infusion 
NAVODILO ZA PRIPRAVO TEPADINA 15 mg prašek za koncentrat za raztopino za infundiranje
Stomatitis Vomiting Diarrhoea Abdominal pain 
Žilne bolezni limfedem hipertenzija krvavitev embolija
The recommended dose ranges from 120 mg/m2/day (3.24 mg/kg/day) to 250 mg/m2/day (6.76 mg/kg/day) as a single daily infusion, administered from 3 up to 5 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 800 mg/m2 (21.62 mg/kg), during the time of the entire conditioning treatment. 
Priporočeni odmerek pri čvrstih tumorjih je od 120 mg/m2 na dan (3,24 mg/kg/dan) do 250 mg/m2 na dan (6,76 mg/kg/dan), kot ena infuzija na dan ali razdeljen na dve infuziji na dan, in se daje 2 do 5 zaporednih dni pred avtologno PKMC, odvisno od kombinacije z drugimi kemoterapevtiki, ne da bi se presegel skupni največji kumulativni odmerek 800 mg/m2 (21,62 mg/kg) v času celotnega pripravljalnega zdravljenja.
Thiotepa might induce pulmonary toxicity that may be additive to the effects produced by other cytotoxic agents (busulfan, fludarabine and cyclophosphamide) (see section 4.8). 
(busulfana, fludarabina in ciklofosfamida) (glejte poglavje 4.8).
Arrhythmia 
ZDRAVILA
Azoospermia Amenorrhoea Vaginal haemorrhage 
Motnje reprodukcije in dojk azoospermija amenoreja vaginalna krvavitev menopavzalni simptomi neplodnost pri ženskah neplodnost pri moških
Asthenia Chills 
Bolezni jeter,
How TEPADINA is given 
Kako se zdravilo TEPADINA uporablja
Uncommon side effects (may affect up to 1 in 100 people) - inflammation and exfoliation of the skin (erythrodermic psoriasis) - delirium, nervousness, hallucination, agitation - gastrointestinal ulcer - inflammation of the muscular tissue of the heart (myocarditis) - abnormal heart condition (cardiomyopathy) 
- delna izguba gibanja - zastoj srca - slabost, bruhanje, driska - vnetje ustne sluznice (mukozitis)
SICKLE CELL ANAEMIA 
ALOGENSKA PKMC Hematološke bolezni
The recommended dose is 185 mg/m2/day (5 mg/kg/day) as a single daily infusion before allogeneic HPCT, without exceeding the total maximum cumulative dose of 185 mg/m2 (5 mg/kg), during the time of the entire conditioning treatment. 
Priporočeni odmerek je 185 mg/m2 na dan (5 mg/kg/dan) v obliki ene infuzije na dan, ki se daje dva zaporedna dneva pred avtologno PKMC, ne da bi se presegel skupni največji kumulativni odmerek 370 mg/m2 (10 mg/kg) v času celotnega pripravljalnega zdravljenja.
Toxic shock syndrome 
citotoksično zdravilo
Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): RRM values ranging from 0% to 2.5% have been reported. 
Z režimom povezana umrljivost in s presaditvijo povezana umrljivost: poročali so o vrednostih RRM med 0 in 2,5 %.
Generalised oedema 
OVOJNINAH VIALA
Infections and infestations 
Linearnost/Nelinearnost